Article Text

Download PDFPDF
Original research
Impact of stress hyperglycemia on outcomes in patients with large ischemic stroke
  1. Xiaolei Shi,
  2. Shihai Yang,
  3. Changwei Guo,
  4. Wenzhe Sun,
  5. Jiaxing Song,
  6. Shitao Fan,
  7. Jie Yang,
  8. Chengsong Yue,
  9. Jiandi Huang,
  10. Linyu Li,
  11. Yan Tian,
  12. Jinfu Ma,
  13. Xu Xu,
  14. Zhixi Wang,
  15. Weilin Kong,
  16. Dongsheng Ye,
  17. Zhouzhou Peng,
  18. Fengli Li,
  19. Wenjie Zi
    1. Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University, Chongqing, China
    1. Correspondence to Dr Wenjie Zi; ziwenjie{at}tmmu.edu.cn

    Abstract

    Background Clinical evidence of the potential influence of stress hyperglycemia ratio (SHR) for patients with large ischemic stroke whether or not receiving endovascular therapy is not clear.

    Methods This study was a subanalysis of a prospective, multicenter registry, and included 745 patients with large ischemic stroke across 38 centers in China. A total of 427 patients were included in this study, with 285 received endovascular therapy (EVT) and 142 received standard medical therapy (SMT). SHR was defined as glucose (mmol/L)/(1.59 × HbA1C)–2.59. The primary outcome was a moderate neurological outcome (modified Rankin Scale (mRS) score ≤3) at 90 days.

    Results A significant interaction was observed between SHR and whether received EVT (p=0.017). Among patients who received EVT (adjusted OR (aOR) 0.46; 95% CI 0.23 to 0.92; p=0.029), patients in the highest tertile of SHR were significantly less likely to achieve a moderate neurological outcome at 90 days compared with those in the lowest tertile. However, this association was not observed in patients receiving SMT (aOR 2.46; 95% CI 0.74 to 8.21; p=0.142). EVT patients with higher SHR had a significantly higher incidence of symptomatic intracranial hemorrhage compared with lower SHR (aOR 3.29; 95% CI 1.08 to 10.06; p=0.036), while such an association was not observed in the SMT group (aOR 1.52; 95% CI 0.56 to 4.12; p=0.410).

    Conclusions In patients with large ischemic stroke treated with EVT, SHR is associated with a reduced likelihood of achieving a moderate neurological outcome, as well as an increased risk of symptomatic intracranial hemorrhage.

    Trial registration number ChiCTR2100051664.

    • Thrombectomy
    • Stroke
    • Intervention
    • Embolic

    Data availability statement

    Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request.

    View Full Text

    Footnotes

    • XS, SY, CG and WS contributed equally.

    • Contributors WZ and FL as the study guarantors had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: XS, SY, CG, WS. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: XS, SY, CG, WS. Critical revision of the manuscript for important intellectual content: XS, SY, CG, WS, JS. Statistical analysis: XS, SY, CG, WS. Administrative, technical, or material support: all authors. Supervision: WZ and FL.

    • Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Natural Science Foundation of China (No. 82071323), National Natural Science Foundation of China (No. 82271349), Academic Excellence Program (2022XKRC003), Chongqing Natural Science Foundation (cstc2020jcyj-msxmX0926), the Army Medical University Clinical Medical Research Talent Training Program (No. 2019XLC2008), and Clinical Medical Research Talents Training Program of Army Military Medical University (2018XLC1005).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.